Asset profile
SHR-1707
Monoclonal antibody
Evidence outlook · lead readout
NCT05681819 · Alzheimer's Disease
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT05681819: The trial randomized 33 participants to SHR-1707 or placebo with triple-blinding, a design able to isolate a genuine drug effect, but its primary outcomes were safety measures rather than a cognitive or functional efficacy endpoint, and results have not yet been posted, so no effect on Alzheimer's disease could be established from this record.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.